» Articles » PMID: 35620578

Sitagliptin Alleviates Radiation-Induced Intestinal Injury by Activating NRF2-Antioxidant Axis, Mitigating NLRP3 Inf--lammasome Activation, and Reversing Gut Microbiota Disorder

Overview
Publisher Wiley
Date 2022 May 27
PMID 35620578
Authors
Affiliations
Soon will be listed here.
Abstract

Radiation-induced intestinal injury is a common and critical complication of radiotherapy for pelvic or abdominal tumors, with limited therapeutic strategies and effectiveness. Sitagliptin, a dipeptidyl peptidase IV (DPP4) inhibitor, has previously been reported to alleviate total body irradiation- (TBI-) induced damage of hematopoietic system in mice, but its effect on radiation-induced intestinal injury remains unclear. In this study, we confirmed that Sitagliptin could not only protect mice from death and weight loss caused by whole abdominal irradiation (WAI) but also improve the morphological structure of intestine and the regeneration ability of enterocytes. In addition, Sitagliptin significantly inhibited the production of radiation-induced proinflammatory cytokines and reduced the number of apoptotic intestinal epithelial cells and -H2AX expression. , we demonstrated that Sitagliptin protected HIEC-6 cells from ionizing radiation, resulting in increased cell viability and reduced DNA damage. Mechanistically, the radiation protection of Sitagliptin might be related to the upregulation of NRF2 level and the decrease of NLRP3 inflammasome activity. Importantly, Sitagliptin significantly restored radiation-induced changes in bacterial composition. In conclusion, our results suggested that Sitagliptin could reduce WAI-induced intestinal injury in mice, which may provide novel therapeutic strategy for radiation-induced intestinal injury.

Citing Articles

Ferulic Acid Interferes with Radioactive Intestinal Injury Through the DJ-1-Nrf2 and Sirt1-NF-κB-NLRP3 Pathways.

Zhang X, Zhang H, Huang M, Mei Y, Hu C, Huang C Molecules. 2024; 29(21).

PMID: 39519712 PMC: 11547899. DOI: 10.3390/molecules29215072.


Metal-organic-framework-based sitagliptin-release platform for multieffective radiation-induced intestinal injury targeting therapy and intestinal flora protective capabilities.

He D, Li Z, Wang M, Kong D, Guo W, Xia X J Nanobiotechnology. 2024; 22(1):631.

PMID: 39415273 PMC: 11484307. DOI: 10.1186/s12951-024-02854-1.


Mechanisms of radiation-induced tissue damage and response.

Zhou L, Zhu J, Liu Y, Zhou P, Gu Y MedComm (2020). 2024; 5(10):e725.

PMID: 39309694 PMC: 11413508. DOI: 10.1002/mco2.725.


Pathology of Diabetes-Induced Immune Dysfunction.

Alexander M, Cho E, Gliozheni E, Salem Y, Cheung J, Ichii H Int J Mol Sci. 2024; 25(13).

PMID: 39000211 PMC: 11241249. DOI: 10.3390/ijms25137105.


Ferroptosis, Inflammation, and Microbiome Alterations in the Intestine in the Göttingen Minipig Model of Hematopoietic-Acute Radiation Syndrome.

Horseman T, Rittase W, Slaven J, Bradfield D, Frank A, Anderson J Int J Mol Sci. 2024; 25(8).

PMID: 38674120 PMC: 11050692. DOI: 10.3390/ijms25084535.


References
1.
Kosowska A, Garczorz W, Klych-Ratuszny A, Aghdam M, Kimsa-Furdzik M, Simka-Lampa K . Sitagliptin Modulates the Response of Ovarian Cancer Cells to Chemotherapeutic Agents. Int J Mol Sci. 2020; 21(23). PMC: 7731375. DOI: 10.3390/ijms21238976. View

2.
Kong L, Deng J, Zhou X, Cai B, Zhang B, Chen X . Sitagliptin activates the p62-Keap1-Nrf2 signalling pathway to alleviate oxidative stress and excessive autophagy in severe acute pancreatitis-related acute lung injury. Cell Death Dis. 2021; 12(10):928. PMC: 8505515. DOI: 10.1038/s41419-021-04227-0. View

3.
Schieffer L, Manzl C, Schatz C, Haybaeck J, Crismani A . Nrf2 in the Field of Dentistry with Special Attention to NLRP3. Antioxidants (Basel). 2022; 11(1). PMC: 8772975. DOI: 10.3390/antiox11010149. View

4.
Lu L, Jiang M, Zhu C, He J, Fan S . Amelioration of whole abdominal irradiation-induced intestinal injury in mice with 3,3'-Diindolylmethane (DIM). Free Radic Biol Med. 2018; 130:244-255. DOI: 10.1016/j.freeradbiomed.2018.10.410. View

5.
Drucker D, Nauck M . The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006; 368(9548):1696-705. DOI: 10.1016/S0140-6736(06)69705-5. View